PETX Aratana Therapeutics Inc

EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Aratana Therapeutics, Inc. - PETX

NEW YORK--(BUSINESS WIRE)--

Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Aratana Therapeutics, Inc. (NASDAQ:PETX) resulting from allegations that Aratana may have issued materially misleading business information to the investing public.

On February 6, 2017, Aratana disclosed that the Center for Veterinary Medicine (“CVM”) had requested more information about Aratana’s appetite stimulation drug ENTYCE. Aratana stated that “it now anticipates that ENTYCE…will be commercially available by late 2017” and that the CVM’s request was in response to Aratana’s “post-approval supplement request to transfer manufacturing of ENTYCE to a new vendor in order to produce ENTYCE at a commercial scale” On this news, shares of Aratana fell $1.44 per share or over 17% to close at $6.59 per share on February 6, 2017.

Rosen Law Firm is preparing a class action lawsuit to recover losses suffered by Aratana investors. If you purchased shares of Aratana on or before February 3, 2017, please visit the firm’s website at http://www.rosenlegal.com/cases-1049.html for more information. You may also contact Phillip Kim or Kevin Chan of Rosen Law Firm toll free at 866-767-3653 or via email at [email protected] or [email protected].

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.

Attorney Advertising. Prior results do not guarantee a similar outcome.

EN
06/02/2017

Underlying

PETXAratana Therapeutics Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Aratana Therapeutics Inc

GlobalData Department
  • GlobalData Department
EUR 227.65
PETX Aratana Therape...

Aratana Therapeutics Inc (PETX) - Pharmaceuticals & Healthcare - Deals...

Summary Aratana Therapeutics Inc (Aratana) is a provider of pet care solutions. The company develops, commercializing and markets biopharmaceutical products for medical condition in cats and dogs. Its pipeline portfolio consists of small molecule pharmaceuticals and large molecule biologics that aim for the treatment serious conditions in pets. Aratana offers products candidates, which include Galliprant (AT-001), for the treatment of osteoarthritis pain and inflammation; Entyce (AT-002), for a...

PETX ARATANA THERAPEUTICS INC
10/23/18 October 23, 2018 19 EN
Free Trial
PETX Aratana Therape...

1 director sold

A director at Aratana Therapeutics Inc sold 75,000 shares at 6.057USD and the significance rating of the trade was 57/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years...

PETX ARATANA THERAPEUTICS INC
09/21/18 September 21, 2018 1 EN
 PRESS RELEASE
Free
PETX Aratana Therape...

INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of a Class...

NEW YORK--(BUSINESS WIRE)-- The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Aratana Therapeutics, Inc. (NASDAQ: PETX) between March 16, 2015 and February 3, 2017. You are hereby notified that Levi & Korsinsky has commenced the class action Dezi v. Aratana Therapeutics, Inc., et al. (Case No. 1:17-cv-01446) in the USDC for the Southern District of New York. To get more information go to: http://www.zlk.com/pslra/arat...

March 22, 2017 1 EN
 PRESS RELEASE
Free
PETX Aratana Therape...

PETX INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors...

NEW YORK--(BUSINESS WIRE)-- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Southern District of New York on behalf of investors who purchased Aratana Therapeutics, Inc. (NASDAQ: PETX) securities between March 16, 2015 and February 3, 2017. Click here to learn about the case: http://www.wongesq.com/pslra/aratana-therapeutics. There is no cost or obligation to you. According to the complaint, throughout the Class Period Defendants made false and/or misleading...

March 17, 2017 1 EN
 PRESS RELEASE
Free
PETX Aratana Therape...

DEADLINE ALERT: Brower Piven Alerts Shareholders Of Approaching Deadli...

STEVENSON, Md.--(BUSINESS WIRE)-- The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of purchasers of Aratana Therapeutics, Inc. (Nasdaq:PETX) (“Aratana” or the “Company”) securities during the period between March 16, 2015 and February 3, 2017, inclusive (the “Class Period”). Investors who wish to become proactively involved in the litigation have until April 7, 2017...

March 14, 2017 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch